All In Biotech

Drug Trial Radar · NCT04630028

A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)

A Phase 3 Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Open-label Intravenous Induction Treatment Followed by Randomized Double-blind Subcutaneous Ustekinumab Maintenance in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

112

Actual

Start

Mar 17, 2021

Primary completion

May 8, 2025

Study completion Jun 5, 2025

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Nov 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate: a) the efficacy of ustekinumab dosing in inducing clinical remission, b) safety profile of ustekinumab, and c) ustekinumab exposure (pharmacokinetics \[PK\]) in pediatric participants with moderately to severely active UC.

Conditions

  • Colitis, Ulcerative

Interventions

  • Ustekinumab Dose Based on BSA and Body WeightDrug

    As per BSA and body weight Ustekinumab will be administered SC and IV.

  • Matching PlaceboDrug

    Placebo will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Global: Percentage of Participants With Clinical Remission at Induction Week 8Time frame: Induction Week 8
  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Induction Period: From induction Week 0 (Study Week 8) up to induction Week 8; Maintenance Period: From Maintenance Week 0 up to Maintenance Week 44 (Study Week 52)
  3. Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)Time frame: Induction Period: From induction Week 0 (Study Week 8) up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
  4. Number of Participants With AEs Leading to Discontinuation of Study InterventionTime frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
  5. Number of Participants With Adverse Events of Special Interest (AESIs)Time frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
  6. Number of Participants With Abnormalities in Clinical Laboratory Parameters: HematologyTime frame: Induction Period: From Induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
  7. Number of Participants With Abnormalities in Clinical Laboratory Parameters: ChemistryTime frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
  8. Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)Time frame: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
  9. Serum Ustekinumab ConcentrationsTime frame: Induction Period: Week I-0, 1-hour pre and post infusion; Week I-2, I-4, and Week I-8; Maintenance Period: Week M-4, M-8, M-12, M-16, M-24, M-32, M-36, and M-44

Locations

58 sites in 9 countries. Site status is shown where the registry gives one.

  • Nemours DuPont Hospital for Children

    Wilmington, Delaware

  • Children's Center for Digestive Health Care

    Atlanta, Georgia

  • Mayo Clinic

    Rochester, Minnesota

  • Morristown Memorial Hospital

    Morristown, New Jersey

  • Levine Childrens at Atrium Health

    Charlotte, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Penn State Hershey Children's Hospital

    Hershey, Pennsylvania

  • Cook Childrens Medical Center

    Fort Worth, Texas

  • Pediatric Specialists Of Virginia

    Fairfax, Virginia

  • Universitair Kinderziekenhuis Koningin Fabiola

    Brussels, Belgium

  • Cliniques Universitaires Saint Luc

    Brussels, Belgium

  • UZ Gent

    Ghent, Belgium

  • UZ Brussel

    Jette, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Universitätsklinikum Aachen

    Aachen, Germany

  • Charite-Universitätsmedizin Berlin - Berlin

    Berlin, Germany

  • Universitatsklinikum Erlangen

    Erlangen, Germany

  • Universitatsklinikum Essen

    Essen, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Dr. von Haunersches Kinderspital

    Munich, Germany

  • KUNO Klinik St. Hedwig

    Regensburg, Germany

  • Universitatsklinikum Ulm

    Ulm, Germany

  • Semmelweis Egyetem

    Budapest, Hungary

  • Debreceni Egyetem Klinikai Kozpont

    Debrecen, Hungary

  • Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz

    Miskolc, Hungary

  • Szabolcs Szatmar Bereg Varmegyei Oktatokorhaz

    Nyíregyháza, Hungary

  • Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum

    Szeged, Hungary

  • Shamir Medical Center Assaf Harofeh

    Be’er Ya‘aqov, Israel

  • Rambam Medical Center

    Haifa, Israel

  • Carmel Medical Center

    Haifa, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Schneider Children's Medical Center

    Petah Tikva, Israel

  • Sheba Medical Center

    Ramat Gan, Israel

  • Juntendo University Hospital

    Bunkyō City, Japan

  • Gunma University Hospital

    Gunma, Japan

  • Kindai University Nara Hospital

    Ikoma, Japan

  • Kurume University Hospital

    Kurume, Japan

  • Saitama Childrens Medical Center

    Saitama Shi, Japan

  • Miyagi Children's Hospital

    Sendai, Japan

  • National Center for Child Health and Development

    Setagaya Ku, Japan

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.